MX2010001903A - Flora intestinal y control de peso. - Google Patents

Flora intestinal y control de peso.

Info

Publication number
MX2010001903A
MX2010001903A MX2010001903A MX2010001903A MX2010001903A MX 2010001903 A MX2010001903 A MX 2010001903A MX 2010001903 A MX2010001903 A MX 2010001903A MX 2010001903 A MX2010001903 A MX 2010001903A MX 2010001903 A MX2010001903 A MX 2010001903A
Authority
MX
Mexico
Prior art keywords
weight management
proteobacteria
relates
present
metabolic disorders
Prior art date
Application number
MX2010001903A
Other languages
English (en)
Inventor
Catherine Mace
Christian Darimont
David Philippe
Fabrizio Arigoni
Chieh Jason Chou
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39688790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010001903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2010001903A publication Critical patent/MX2010001903A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/127—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invenci?n se refiere a apoyar el control de peso, la p?rdida de peso y/o la prevenci?n y/o tratamiento de los trastornos metab?licos. En particular la presente invenci?n se refiere a prevenir y/o tratar los trastornos metab?licos por modulaci?n, en particular reduciendo la cantidad de proteobacterias y/o deferribacteres en el intestino. Una modalidad de la presente invenci?n se refiere al uso de una composici?n primaria que comprende un agente que reduce la cantidad de proteobacteria, preferentemente gama-proteobacteria, a?n m?s preferentemente enterobacteria; y/o deferribacteres en el intestino para la preparaci?n de una composici?n para tratar o prevenir los trastornos metab?licos, para apoyar la p?rdida de peso y/o apoyar al control de peso.
MX2010001903A 2007-08-17 2008-07-25 Flora intestinal y control de peso. MX2010001903A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114530A EP2030623A1 (en) 2007-08-17 2007-08-17 Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
PCT/EP2008/059809 WO2009024429A2 (en) 2007-08-17 2008-07-25 Gut flora and weight management

Publications (1)

Publication Number Publication Date
MX2010001903A true MX2010001903A (es) 2010-04-30

Family

ID=39688790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001903A MX2010001903A (es) 2007-08-17 2008-07-25 Flora intestinal y control de peso.

Country Status (10)

Country Link
US (1) US8591880B2 (es)
EP (2) EP2030623A1 (es)
CN (2) CN101827600A (es)
AR (1) AR067971A1 (es)
AU (1) AU2008290737B2 (es)
BR (1) BRPI0815506A2 (es)
CL (1) CL2008002422A1 (es)
MX (1) MX2010001903A (es)
SG (1) SG2014014153A (es)
WO (1) WO2009024429A2 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
FI20080321A0 (fi) * 2008-04-25 2008-04-25 Eino Elias Hakalehto Menetelmä suoliston bakteeritasapainon ylläpitämiseksi
JP5322556B2 (ja) * 2008-09-19 2013-10-23 株式会社Ｍｃｂｉ 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法
KR20110124780A (ko) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
WO2010106384A1 (fr) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Compositions nutraceutiques, pharmaceutiques ou alimentaires a base de gluco-oligosaccharides
EP2422813A4 (en) * 2009-04-22 2014-07-23 Fujifilm Corp MEANS FOR CONTROLLING THE COMPOSITION OF THE DARM BACTERIA FLORA
CA2762665A1 (en) 2009-05-19 2010-11-25 Unilever Plc A prebiotic composition comprising thearubigin
US20120107291A1 (en) 2009-06-19 2012-05-03 Danisco A/S Bifidobacteria for treating diabetes and related conditions
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
FR2955495B1 (fr) * 2010-01-27 2012-05-11 Biocodex Medicament pour la reduction de la cholesterolemie
ES2916399T3 (es) 2010-02-01 2022-06-30 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
EP2449890A1 (en) * 2010-11-05 2012-05-09 Nestec S.A. Powdered cereal compositions comprising non-replicating probiotic microorganisms
WO2012122478A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US20140086954A1 (en) * 2011-03-31 2014-03-27 Chu De Toulouse Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
ITMI20111488A1 (it) * 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
EP2797606A4 (en) 2011-08-17 2015-09-30 MicroBiome Therapeutics LLC COMPOSITION AND USE OF A FORMULATION FOR INCREASING THE REPORT OF THE GASTROINTESTINAL MICROBIOTE OF THE PHYLUM OF BACTERIODITIES TO THE MICROBIOTE OF THE PHYLUM OF FIRMICUTES
GB2511993B (en) * 2011-11-30 2019-09-18 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2014019271A1 (en) * 2012-08-01 2014-02-06 Bgi Shenzhen Biomarkers for diabetes and usages thereof
EP3967315A1 (en) * 2012-11-19 2022-03-16 Université catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
CN105074460B (zh) * 2013-03-28 2018-06-15 雀巢产品技术援助有限公司 作为用于重量增加预防的益生元功效的生物标记物的硫酸吲哚酚
WO2014177667A1 (en) * 2013-05-03 2014-11-06 Nestec S.A. Lachnospiraceae in the gut microbiota and association with body weight
JP6330032B2 (ja) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法組成物を製造、処理、および梱包するための方法
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
DK3022313T3 (en) * 2013-07-18 2017-04-18 Nestec Sa ESCHERICHIA COLI AS A MARKER FOR HYPERTRIGLYCERY DIMM
CN104413334A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
CN105899090A (zh) * 2013-11-07 2016-08-24 三得利控股株式会社 包含乳酸菌的肠道屏障功能促进剂
EP2870969A1 (fr) * 2013-11-08 2015-05-13 Biocodex Composition pharmaceutique pour la réduction de la masse adipeuse
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
AP2016009626A0 (en) * 2014-05-16 2016-12-31 Internat Ct Of Insect Physiology And Ecology Antimicrobial agents produced by xenorhabdus griffiniae strain xn45
CN106659226A (zh) * 2014-08-18 2017-05-10 雀巢产品技术援助有限公司 用于降低以后生命中肥胖风险的益生元
CA2962907C (en) * 2014-10-02 2022-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof
SG11201703395PA (en) 2014-10-31 2017-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
US11058131B2 (en) 2015-04-16 2021-07-13 Kennesaw State University Research And Service Foundation, Inc. Escherichia coli O157:H7 bacteriophage Φ241
CN106148179A (zh) * 2015-04-23 2016-11-23 上海复星长征医学科学有限公司 葡萄球菌药敏板条及其制备方法
AU2016257315A1 (en) 2015-05-06 2017-11-23 Université Catholique de Louvain Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
NZ776366A (en) 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
AU2016271303C1 (en) * 2015-06-01 2022-04-14 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
EP3939601A1 (en) 2015-06-09 2022-01-19 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CN114276960A (zh) 2015-09-10 2022-04-05 卢万天主教大学 经巴氏灭菌的艾克曼菌用于治疗代谢病症的用途
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
KR20180049731A (ko) * 2016-11-03 2018-05-11 주식회사 쎌바이오텍 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
AU2017366923B2 (en) 2016-12-02 2021-09-02 Fairlife, Llc Non-browning lactose-free milk powder and methods of making same
EP3551290A4 (en) * 2016-12-12 2020-12-23 GI Dynamics, Inc. THERAPEUTIC PROCEDURES WITH GASTROINTESTINAL IMPLANTS
KR101833503B1 (ko) * 2016-12-26 2018-03-05 주식회사 엠디헬스케어 만성폐쇄성폐질환자에서 세균 메타게놈 분석을 통한 폐암 진단방법
CA3046705A1 (en) 2017-02-10 2018-08-16 Perfect (China) Co., Ltd. Novel probiotics bifidobacteria strains
CN110402148A (zh) * 2017-03-14 2019-11-01 布莱阿姆青年大学 用噬菌体治疗肥胖症、炎症或代谢病症的方法和组合物
AU2018250206A1 (en) 2017-04-05 2019-10-31 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (PD) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
KR102019646B1 (ko) * 2017-06-07 2019-09-10 주식회사 엠디헬스케어 미생물 메타게놈 분석을 통한 아토피피부염 진단방법
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CN107898815A (zh) * 2017-12-07 2018-04-13 生物源生物技术（深圳）股份有限公司 一种动物用灭活乳酸菌制剂及其用途
WO2019226950A1 (en) * 2018-05-23 2019-11-28 Brigham Young University Bacteriophage compositions and kits and related methods
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods
EP3594321A1 (en) 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
CN111714522B (zh) * 2019-03-04 2022-07-15 中国科学院微生物研究所 拟杆菌及其应用
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
TW202207955A (zh) * 2020-05-05 2022-03-01 香港商香港微生物菌群創新中心有限公司 診斷和治療代謝疾病的方法
JP2024033027A (ja) * 2021-01-22 2024-03-13 国立研究開発法人産業技術総合研究所 糖尿病誘起細菌に感染するバクテリオファージ及びその用途
CN114438236B (zh) * 2021-12-07 2023-04-11 南京医科大学 肠道脱硫弧菌在筛选胆囊胆固醇结石病高危人群及防治药物中的应用
CN116473222A (zh) * 2022-01-17 2023-07-25 中国科学院上海营养与健康研究所 调控脂质吸收的方法、组合物及其应用
FR3138770A1 (fr) * 2022-08-10 2024-02-16 Actina Ensemble de parties destine a moduler le microbiote intestinale, reduire la prise de poids et le stockage des graisses dans le foie

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
JPH04253918A (ja) * 1991-02-05 1992-09-09 Mitsui Norin Kk 血糖上昇抑制剤
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
US6525182B1 (en) * 2000-01-21 2003-02-25 Regents Of The University Of California Guanidinylation, guanidinoglycosides, uses, and methods of assaying their activity
US6485902B2 (en) 2000-06-06 2002-11-26 Thomas E. Waddell Use of bacteriophages for control of escherichia coli O157
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
RU2314096C2 (ru) 2002-05-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Синергическая фармацевтическая композиция для лечения лейкемии
WO2003101445A1 (en) * 2002-06-03 2003-12-11 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
FR2844453B1 (fr) * 2002-09-13 2006-05-19 Agronomique Inst Nat Rech Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
CA2467695C (en) * 2003-05-20 2010-03-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Isomaltooligosaccharides from leuconostoc as neutraceuticals
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
JP2006273741A (ja) * 2005-03-29 2006-10-12 Meiji Seika Kaisha Ltd ＰＰＡＲγリガンド活性を有する組成物
US7674484B2 (en) * 2005-04-18 2010-03-09 Integrity Nutraceuticals International Dietary supplement including He Shou Wu, parasitic loranthus and green tea to promote weight loss
GB0511204D0 (en) 2005-06-02 2005-07-06 Univ Birmingham Medicaments
SE529185C2 (sv) 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
DK1981516T3 (en) 2006-01-27 2018-12-03 Dupont Nutrition Biosci Aps APPLICATION OF PROBIOTIC MICROORGANISMS FOR TREATMENT AND PREVENTION OF OBESIS AND RELATED DISORDERS
EP1886680A1 (en) * 2006-05-23 2008-02-13 Nestec S.A. Maternal supplement
EP2102350A4 (en) * 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
EP1974734A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
EP2022502A1 (en) * 2007-08-10 2009-02-11 Nestec S.A. Lactobacillus rhamnosus and weight control

Also Published As

Publication number Publication date
CN101827600A (zh) 2010-09-08
BRPI0815506A2 (pt) 2015-02-10
EP2190438A2 (en) 2010-06-02
US20110123501A1 (en) 2011-05-26
AU2008290737A1 (en) 2009-02-26
CN104147052A (zh) 2014-11-19
CL2008002422A1 (es) 2009-10-23
US8591880B2 (en) 2013-11-26
AR067971A1 (es) 2009-10-28
AU2008290737B2 (en) 2013-11-14
WO2009024429A2 (en) 2009-02-26
SG2014014153A (en) 2014-05-29
EP2030623A1 (en) 2009-03-04
WO2009024429A3 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
MX2010001903A (es) Flora intestinal y control de peso.
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
TW200640454A (en) Method for treating obesity
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EP3318262A3 (en) Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
MX2009011366A (es) Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13.
PH12016501607B1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
MX2009003911A (es) Formulaciones de liberacion inmediata, mejoradas de topiramato.
EP3085365A3 (en) Synergistic combinations of carotenoids and polyphenols
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
MX342305B (es) Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina.
UA96076C2 (en) Use of trans-clomiphene
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
ZA202110111B (en) Methods and compositions for treating liver disorders
MX2013008729A (es) Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MX2012006629A (es) Microorganismos probioticos como agentes activos contra cambios en microrelieve de la piel.
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
WO2011044523A3 (en) Compositions and methods for treating obesity
ZA201008160B (en) Compositions for the treatment of hair loss

Legal Events

Date Code Title Description
FG Grant or registration